Nov 1, 2025 | News |
The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid Services and all seven Medicare Administrative Contractors as a formal sovereign...
Oct 28, 2025 | News |
A STATEMENT FROM THE OFFICE OF THE CEO Issued by Clear Health Pass Holdings, LLC, as Authorized Tribal Agent It has come to the attention of Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium,...
Sep 16, 2025 | News |
The Tribal Biotechnology & Health Consortium’s full sovereign submission on the CY 2026 Medicare Physician Fee Schedule has been posted publicly on Regulations.gov, the federal government’s official rulemaking record platform, under Comment ID CMS-2025-0304-13291....
Sep 12, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed its formal sovereign comment on the proposed CY 2026 Medicare Physician Fee Schedule (CMS-1832-P), continuing a coordinated, multi-docket engagement with the Centers for Medicare & Medicaid Services. The...
Sep 4, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed its formal comment on the proposed CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule (CMS-1834-P), addressing the proposed treatment of skin substitute...
Jul 28, 2025 | News |
Clear Health Pass Holdings, on behalf of the Tribal Biotechnology & Health Consortium, today announced the appointment of David Burke, MD, MA as Principal Investigator for the post-market clinical validation of Rampart™ DL Matrix (Q4347). Dr. Burke is Department...